Drug Database
ES

estradiol (Vagifem)

✓ Approved

Novo Nordisk A/S · ESR1 · 小分子

什么是 estradiol?

estradiol 是一种小分子,由Novo Nordisk A/S研发。该药已获批,用于治疗相关适应症,给药途径:Intravaginal。

药物档案

商品名Vagifem
公司Novo Nordisk A/S
药物类别小分子
分子靶点ESR1
给药途径Intravaginal
状态Approved

作用机制

分子靶点

estradiol 作用于 1 个分子靶点:

ESR1estrogen receptor 1 (ER, ESR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

estradiol 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Reproductive system and breast disordersAtrophic vulvovaginitis✓ Approved

相关研究文献

PubMedCells2026-10-26

The Vaginal Microbiome-Mitochondria Axis: Implications for Genital Tract Infections.

Agoni Lorenzo L, Pericolini Eva E, Salvatore Stefano S, Candiani Massimo M et al.

The vaginal microbiome influences epithelial and immune homeostasis through microbial metabolites, virulence factors, and other molecular signals, yet intracellular mechanisms translating microbial activity into host responses remain largely unexplored. Here, we propose the vaginal microbiome-mitochondria axis as a functional framework linking microbial activity to host-cell metabolism, redox signaling, immunity, and cell fate. We integrated evidence from vaginal microbiology, mitochondrial biology, mucosal immunology, and immunometabolism, distinguishing direct observations in the female genital tract from mechanistic evidence obtained in other host-microbe systems. Available evidence indicates that microbial products relevant to vaginal homeostasis and dysbiosis can modulate mitochondrial bioenergetics, reactive oxygen species generation and redox signaling, membrane potential, dynamics, and quality control pathways, while mitochondrial responses can influence epithelial integrity and antimicrobial and inflammatory functions. We further propose that the balance between mitochondrial adaptation and dysfunction may contribute to resolution or persistence of vaginal disorders and that incomplete mitochondrial recovery could contribute to an incomplete microbial ecosystem-host reset and recurrence. Although direct vaginal evidence remains limited, this framework identifies mitochondria as a potentially important functional interface between microbial ecology and host response and generates testable hypotheses for investigating whether mitochondrial homeostasis contributes to durable resolution of vaginal dysbiosis and infection.

PMID 42929808
阅读全文 →
PubMedThe journal of obstetrics and gynaecology research2026-10-26

Vaginal Angiomyofibroblastoma in a Patient With Warkany Syndrome (Mosaic Trisomy 8): A Case Report.

Amaireh Enas A EA, Marahleh Marah M, Al-Hussaini Maysa M, Mahfouz Ismaiel Abu IA

Warkany syndrome, or mosaic trisomy 8, is a rare chromosomal disorder characterized by craniofacial dysmorphism, skeletal anomalies, and urogenital malformations, with no previously reported association with solid mesenchymal neoplasia. Angiomyofibroblastoma is an extremely rare benign mesenchymal tumor of the lower female genital tract with a largely uncharacterized cytogenetic background. We describe a 27-year-old nulliparous woman with constitutionally confirmed mosaic trisomy 8, established in childhood by peripheral blood karyotype, who presented with a protruding vaginal mass. Magnetic resonance imaging demonstrated a well-defined, homogeneously enhancing mid-vaginal mass and incidentally revealed uterus didelphys and bilateral ureteral ectopia, both recognized urogenital features of this syndrome. Complete surgical excision was performed, and histopathology with immunohistochemistry confirmed angiomyofibroblastoma. This is, to our knowledge, the first reported co-occurrence of angiomyofibroblastoma and Warkany syndrome. Chromosome 8 status of the tumor was not evaluated, so any biological or causal relationship between constitutional trisomy 8 and tumor development remains hypothetical, and the co-occurrence may be coincidental.

PMID 42928509
阅读全文 →
PubMedCells2026-10-26

Selective Estradiol Sensitivity in 12Z Human Endometriotic Epithelial Cell Line.

Banerjee Shohini S, Chopra Esha E, Smith Ian M IM, Stroka Kimberly M KM

Estradiol (E2) is a potent estrogen molecule that plays a crucial role in regulating numerous healthy and pathophysiological processes. To model estrogen-dependent cellular activities in vitro in a physiologically meaningful way, cells chosen for experimentation should exhibit sensitivity to E2. The 12Z human endometriotic epithelial cell line is gaining attention as a model for estrogen-dependent conditions, but its functional responsiveness to E2 has not been well characterized. For the passage range in the following study, we found that E2 does not statistically significantly influence 12Z proliferation, wound closure, or single-cell migration. However, 12Zs were selectively responsive to E2 in 3D migration models where the cells were physically confined. Upregulating ESR1, the primary mediator of estrogenic action, in the 12Zs did not enhance their functional E2 sensitivity. These results highlight the importance of verifying hormone responsiveness when using 12Z cells to model estrogen-dependent processes and conditions.

PMID 42929847
阅读全文 →
PubMedWomen's health (London, England)2026-10-26

Prevalence of bacterial vaginosis, trichomoniasis and vulvovaginal candidiasis among symptomatic women attending selected health centers in Addis Ababa, Ethiopia.

Gesese Yonas Alem YA, Abegaz Woldaregay Erku WE, Mihret Adane A, Birhanu Muluken M et al.

BackgroundSymptomatic vaginal discharge caused by bacterial vaginosis, trichomoniasis, and vulvovaginal candidiasis is a common gynecological issue among reproductive-age women in Sub-Saharan Africa.ObjectivesThis study aimed to determine etiologies and associated risk factors in symptomatic women attending selected health centers in Addis Ababa, Ethiopia.DesignA cross-sectional study was conducted from October 2023 to October 2024, on 347 symptomatic women.MethodsSaline, KOH wet-mount and gram-stain microscopy was used to diagnose trichomoniasis, vulvovaginal candidiasis and bacterial vaginosis respectively. Descriptive analysis and multivariate logistic regressions identified factors associated with outcomes.ResultsThe overall prevalence of overall vaginal infection was 55.6%, led by bacterial vaginosis (44.4%), vulvovaginal candidiasis (20.6%) and trichomoniasis (12.7%). The most common co-infection was BV and VVC (10.1%), followed by BV and TV (4.9%) and VVC+TV (2.0%). Triple infection was detected in 0.9% (95% CI: 0.2-2.5%) of participants. Cigarette smoking was protective against bacterial vaginosis (AOR = 0.57, p = 0.029). Trichomoniasis risk lowered with increasing age (25-34 years: AOR = 0.29, p = 0.001; 35-44 years: AOR = 0.06, p = 0.006) and showed a frequency-dependent association with traditional "Weyba tis" use: protective at less than once monthly (AOR = 0.29, p = 0.007) but a risk factor for at higher frequencies (AOR = 4.01, p = 0.003). Vulvovaginal candidiasis showed lower odds in women with 3 to 5 lifetime sexual partners (AOR = 0.18, p = 0.005).ConclusionsOur study revealed relatively high prevalence vaginal infections highlighting the need for regular assessment and targeted reproductive health education. Larger studies with comprehensive behavioral assessment and etiologic testing are warranted to better elucidate the predictor variables.

PMID 42929181
阅读全文 →
PubMedUrogynecology (Philadelphia, Pa.)2026-10-26

Breastfeeding and Genitourinary Symptoms: A Prospective Cohort Study.

Illston Jana D JD, McMinn Erin K EK, McIlwraith Claire A CA, McGraw Margeaux R MR et al.

Understanding genitourinary effects of breastfeeding allows for proactive treatments and quality-of-life improvements. The objective of this study was to estimate the effect of breastfeeding on genitourinary symptoms. This prospective cohort study of breastfeeding (BF) versus non-breastfeeding (NB) primiparous women characterized genitourinary symptoms after singleton delivery at ≥34 weeks of gestation. Validated measures included the Urinary Distress Inventory-6 (UDI-6), Incontinence Impact Questionnaire-7 (IIQ-7), Most Bothersome Symptom questionnaire (MBS), and Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). Questionnaires were completed at baseline, 6 weeks, 3 months, and 6 months postpartum. The primary outcome was the UDI-6 score at 3 months. Multivariable linear and logistic regression models were evaluated for group differences. UDI-6 scores at 3 months were not different between groups (5.6±11.8 BF, 7±12 NB, P=0.43). Differences in IIQ-7 scores were not statistically significant (4.9±7.4 BF, 13.5±25.2 NB, P=0.07). Multivariable analysis for those not sexually active revealed better partner-related scores in the BF group (β, -0.85; 95% CI, -1.58, -0.12, P=0.024). Among those sexually active, the BF group had worse condition impact scores (β, 0.29; 95% CI, 0.11, 0.47, P=0.002). The three-month MBS revealed nearly a threefold likelihood of experiencing vaginal dryness in BF (adjusted odds ratio, 2.82; 95% CI, 1.19, 6.66, P=0.018). At 6 months, vaginal dryness was no longer different, but breastfeeding continued to affect sexual function. At 3-months postpartum, there were no differences in lower urinary tract symptom severity between BF versus NB women. The BF group had increased bothersome vaginal symptoms and a mixed effect on sexual function. Awareness of these findings should lead to proactive assessment of symptoms and timely treatments.

PMID 42929799
阅读全文 →
PubMedBMC cancer2026-10-26

Prognostic stratification by the ESTRO/EORTC oligometastatic classification and simplified binary approaches in lung cancer patients treated with stereotactic ablative radiotherapy.

Yao Dan D, Zhu Xue-Ru XR, Guo Jin-Dong JD, Song Xin-Yun XY et al.

The ESTRO/EORTC classification categorizes oligometastatic disease (OMD) into de-novo, repeat, and induced OMD based on prior disease history and treatment status. However, its prognostic relevance in lung cancer patients treated with stereotactic ablative radiotherapy (SABR) remains incompletely characterized in real-world settings. This study evaluated the ESTRO/EORTC classification and two simplified binary stratification approaches derived from its decision framework. This single-center retrospective study included 648 lung cancer patients with 1-5 metastases treated with SABR between 2015 and 2021. Patients were categorized according to the ESTRO/EORTC classification. Two simplified binary stratification approaches derived from the ESTRO/EORTC decision framework were additionally explored: (1) a history-based approach distinguishing patients with prior polymetastatic disease from those without, and (2) a therapy-dependent progression approach distinguishing oligometastatic progression during active systemic therapy from other OMD states. Survival outcomes were analyzed using Kaplan-Meier and Cox regression, and prognostic discrimination was assessed using Harrell's C-index. With a median follow-up of 54.5 months, 325 deaths and 552 progression events were observed. Induced OMD was associated with significantly worse outcomes compared with de-novo OMD (OS: 35.7 vs. 68.9 months; PFS: 8.6 vs. 15.5 months; both p < 0.001) and repeat OMD (OS: 35.7 vs. 60.2 months; PFS: 8.6 vs. 14.4 months; both p < 0.001). No significant differences were observed between de-novo and repeat OMD. The therapy-dependent progression stratification approach demonstrated distinct survival separation (median OS 34.4 vs. 86.4 months; PFS 8.4 vs. 16.4 months; both p < 0.001), although the difference in discriminatory performance was modest (C-index 0.596 for OS) compared with the ESTRO/EORTC classification (0.565) and the history-based approach (0.563). Differences in discriminatory performance were modest and not statistically significant after multiple-testing correction and bootstrap resampling. The ESTRO/EORTC classification is associated with survival outcomes in lung cancer patients with OMD treated with SABR, with induced OMD conferring the poorest prognosis. Simplified binary stratification approaches derived from this framework may provide a pragmatic and clinically accessible approach for risk stratification. These approaches should be considered complementary to, rather than replacements for, the full ESTRO/EORTC classification. Prospective validation is warranted.

PMID 42928202
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多estradiol